Data Sheet (Cat.No.T22277L)

TargetMol

BMS-P5 free base

Chemical Properties



CAS No. : 1550371-22-6

Formula: C27H32N6O2

Molecular Weight: 472.58

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor that blocks the formation of Neutrophil Extracellular Traps and delays the progression of multiple myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays symptom onset and disease progression. Targeting PAD4 may be beneficial for treating multiple myeloma.
Targets(IC50)	PAD
In vivo	Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression.

Solubility Information

Solubility	DMSO: 10 mg/mL (21.16 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.12 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.116 mL	10.5802 mL	21.1604 mL
5 mM	0.4232 mL	2.116 mL	4.2321 mL
10 mM	0.2116 mL	1.058 mL	2.116 mL
50 mM	0.0423 mL	0.2116 mL	0.4232 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Li M , Lin C , Deng H , et al. A novel peptidylarginine deiminase 4 (PAD4) inhibitor BMS-P5 blocks formation of neutrophil extracellular traps and delays progression of multiple myeloma[J]. Molecular Cancer Therapeutics, 2020, 19(7):molcanther.1020.2019.